Division Lead — Professor Oleg I. Kiselev, PhD, Dr.Biol.Sci., full member of the Russian Academy of Medical Sciences
Phone: +7 (812) 499–15–00
E-mail: office@influenza.spb.ru
Together with research departments and laboratories of RII, Division of Clinical and Experimental Investigations is pursuing new ways of diagnosing and curing viral infections. The Division manages the process of screening and testing new compounds with antiviral activity, and conducts preclinical trials, including animal testing. A team of virologists, pharmacologists, infectologists and medical specialists develop dosage schemes and protocols for future clinical trials.
Currently, the Division is concentrating on medicine against viral infections with pandemic potential, like Triazavirin, a novel preparation with wide range of use, developed jointly with RAS Ural Institute of Organic Synthesis. Triazavirin shows activity against influenza A H5N1 and H1N1/2009. It proved to be safe and tolerable during Phase I Clinical Trial. Phase II Trial of Triazavirin is currently in progress.
Division of Clinical and Experimental Investigations offers its expertise and research capacity to 3rd party contractors —pharmaceutical companies and research organizations.
